Solriamfetol in excessive daytime sleepiness: a profile of its use

AbstractOral solriamfetol (Sunosi ™), a selective dopamine and norepinephrine reuptake inhibitor, is approved to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnoea (OSA) in the USA and EU. In phase 3 trials in patients with narcolepsy or OSA, relative to pla cebo, solriamfetol within the recommended dosage for narcolepsy (75–150 mg/day) or OSA (37.5–150 mg/day) improved wakefulness and reduced sleepiness, together with patient- and clinician-rated global improvements. The clinical benefits of solriamfetol were maintained with longer-term treatment . Solriamfetol is generally well tolerated, with most adverse events being of mild to moderate severity.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research